SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogelon Mars

Dogelon Mars is trending as investors debate the project's long-term viability versus its status as a legacy meme coin, with the community actively tracking potential exchange listings and social media activity. Participants are polarized between those waiting for a major token burn or market breakout and others who view the asset as a speculative gamble compared to leading cryptocurrencies.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is facing significant market volatility as investors weigh disappointing early-stage cystic fibrosis clinical data against the company's strong cash position and pipeline potential. Community sentiment remains polarized, with some investors viewing the sharp price decline as an overreaction and a buying opportunity, while others are concerned about the lack of near-term catalysts and long-term commercial viability.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing significant community polarization, as long-term holders continue to emphasize long-term accumulation despite persistent price volatility and skepticism from traders questioning the lack of immediate upward momentum. The conversation centers on technical chart patterns and shifting macro indicators, with retail participants debating whether current levels represent a strategic entry point or a continuation of a downward trend.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently drawing significant attention from investors as it navigates market volatility, with community members actively discussing accumulation strategies and potential price rebounds. The discourse is heavily fueled by speculative interest in meme coin cycles, comparisons to other frog-themed tokens, and optimistic outlooks on institutional liquidity as market participants position for future potential gains.

Bank of Montreal engages in the provision of banking and financial services to individuals and institutions. It operates through the following segments: Canadian Personal and Commercial Banking (Canadian P&C), United States Personal and Commercial Banking (U.S. P&C), BMO Wealth Management, BMO Capital Markets, and Corporate Services. The company was founded by Robert Armour, John C. Bush, Austin Cuvillier, George Garden, Horatio Gates, James Leslie, George Moffatt, John Richardson and Thomas A. Turner on June 23, 1817 and is headquartered in Toronto, Canada.

Bank of Montreal - MicroSectors Gold Miners -3X Inverse Leveraged ETNs

GDXD is capturing significant trader attention as a high-volatility play for those seeking to hedge or speculate against the relentless upward momentum in precious metals. The community is actively debating the timing of a potential gold correction, with many traders using it as a tactical tool to capitalize on daily swings while others warn of the risks associated with long-term decay in leveraged inverse ETFs.

Stack Capital Group, Inc. operates as an investment holding company. It engages in making investments on growth to late-stage private issuers with long-term growth potential, located primarily in, or with customers, suppliers or business primarily conducted in or dependent on, Canada and the United States. The firm's objective is to maximize its long-term capital appreciation by seeking to achieve superior risk-adjusted investment performance. The company was founded on April 1, 2021 and is headquartered in Toronto, Canada.

Stack Capital Group Inc

Stack Capital Group is attracting investor interest as an overlooked, low-float vehicle providing indirect exposure to major private assets like SpaceX and CoreWeave. The community is actively highlighting a perceived valuation gap between the firm's private portfolio holdings and its current trading price, positioning it as a potential alternative to more widely tracked space-themed investments.

What is Tron? Tron's mission is to build a truly decentralized internet and aims to be the largest blockchain-based operating system in the world, known as the TRON protocol. The TRON protocol will offer high scalability, high availability, and high throughput computing to serve decentralized applications via smart contracts. Ethereum EVM-based smart contracts will be compatible and deployable on the TRON network as such Solidity developers do not have to rewrite their applications.  Why Tron? Since TRON protocol does not rely on proof of work or mining, instead governed by nodes located around the world, it is decentralized while providing high throughput for transactions on the blockchain. This is suitable for dapps that require high speed transactions especially games. There are a number of tokens already issued on the TRON network and the decentralized exchanges TRX.market has launched.  On July 24th 2018, TRON acquired BitTorrent, one of the largest P2P file sharing protocol. As a result of the acquisition, BitTorrent Token (BTT) was launched as the cryptocurrency to power the economics on the BitTorrent network. The Token will be used to inceltivize file sharing and storage within the network.

Tron

Tron is generating significant community interest driven by its expanding role in global stablecoin transfers and recent strategic cloud partnerships. Investors remain bullish on its long-term network growth, while ongoing discussions focus on its resilience and potential for broader institutional adoption.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience.   The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency &lt;1 second. The chain currently supports 100k orders / second.  The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1.   The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

Hyperliquid ($HYPE) is capturing significant attention as traders debate its long-term utility versus competitors like Aster and Avantis, while community discussions remain split between those bullish on its deflationary tokenomics and others wary of upcoming token unlocks. The conversation is heavily focused on HYPEs role as a dominant decentralized perpetual exchange, with investors closely watching its institutional volume growth and the potential for a broader market rotation into perp-DEX platforms.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

AMGEN is trending due to anticipation surrounding its upcoming earnings report and investor interest in the late-stage development of its obesity candidate, MariTide. The community remains focused on how the company's established drug portfolio, including Repatha and Evenity, will balance potential pricing headwinds while navigating a competitive landscape for cardiometabolic treatments.

CVR Energy, Inc. is a holding company. The firm engages in the petroleum refining and marketing business. It operates through the following segments: Petroleum, Renewables and Nitrogen Fertilizer. The Petroleum segment refines and markets high value transportation fuels. The Renewables segment includes the operations of the renewable diesel unit. The Nitrogen Fertilizer segment markets nitrogen fertilizers primarily in the form of UAN and ammonia. The company was founded in September 1906 and is headquartered in Sugar Land, TX.

CVR Energy Inc

CVR Energy is trending as investors weigh significant operational setbacks, including recent refinery fires and power outages, against the potential for a rebound driven by high-profile insider accumulation from Carl Icahn. The community is actively debating the company's dividend sustainability and its long-term strategic value in a volatile energy market, with many focused on whether current share prices present an overlooked opportunity or a warning sign.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and...

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and...

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences...

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PR...

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 MetaVia Builds Comprehensive Global Patent Protection...

What Does the Market Think About MetaVia Inc?

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering...

MetaVia Stock Slides After Pricing Public Offering

(RTTNews) - MetaVia Inc. (MTVA) shares traded at $3.4050, down 39.03% or $2.18 lower, after the company announced the pricing of an $8.1 million underwritten public offering...

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering PR Newswire CAMBRIDGE, Mass., Jan. 15, 2026...

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic...

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

Current Price	$1.41
Prev Close	$1.48
Open	$1.49
Dividend Yield	0.00%
50-Day Moving Average	$2.47
Beta	0.96
Avg. Volume	339,391.83
PE Ratio	-0.09

52-Week High	$23.10
52-Week Low	$1.34
Market Capitalization	$4.67M
EPS (Annual)	-$39.13
Price to Book	0.49
Revenue Per Employee	$0.00

MTVA
MetaVia Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest MTVA News

MTVAMetaVia Inc.